Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.84 USD | +0.79% | -3.81% | -53.55% |
May. 08 | Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating | MT |
May. 08 | Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.55% | 560M | |
+39.36% | 734B | |
+32.83% | 591B | |
-6.11% | 350B | |
+14.94% | 315B | |
+2.20% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+5.83% | 161B |
- Stock Market
- Equities
- EYPT Stock
- News EyePoint Pharmaceuticals, Inc.
- EyePoint Pharmaceuticals Grants Betta Pharmaceuticals Rights to Commercialize Chronic Eye Disorder Treatment in China